C-X-C Chemokine Receptor (CXCR) Inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 24 Hours
DelveInsight’s, “C-X-C Chemokine Receptor (CXCR) Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in C-X-C Chemokine Receptor (CXCR) Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
C-X-C Chemokine Receptor (CXCR) Inhibitors: Overview
CXCRs (CXC chemokine receptors) are integral membrane proteins that specifically bind and respond to cytokines of the CXC chemokine family. They represent one subfamily of chemokine receptors, a large family of G protein-linked receptors that are known as seven transmembrane (7-TM) proteins, since they span thecell membrane seven times. There are currently seven known CXC chemokine receptors in mammals, named CXCR1 through CXCR7. CXCR1 and CXCR2 are closely related receptors that recognize CXC chemokines that possess an E-L-R amino acid motif immediately adjacent to their CXC motif. CXCR3 is expressed predominantly on T lymphocytes. CXCR4 is the receptor for a chemokine known as CXCL12 (or SDF-1) and, as with CCR5, is utilized by HIV-1 to gain entry into target cells.
The chemokine receptor CXCR5 is selectively expressed on B cells and is involved in lymphocyte homing and the development of normal lymphoid tissue. CXCR6 was formerly called three different names (STRL33, BONZO, and TYMSTR) before being assigned CXCR6 based on its chromosomal location and its similarity to other chemokine receptors in its gene sequence. CXCR7 was originally called RDC-1 (an orphan receptor) but has since been shown to cause chemotaxis in T lymphocytes in response to CXCL12 (the ligand for CXCR4) prompting the renaming of this molecule as CXCR7.
Report Highlights
This segment of the C-X-C Chemokine Receptor (CXCR) Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
C-X-C Chemokine Receptor (CXCR) Inhibitors Emerging Drugs
Motixafortide - BL-8040 (formerly known as BKT140 and developed by Biokine Therapeutics Ltd.) is a novel selective inhibitor of the CXCR4 chemokine receptor that is currently being developed for several indications including treatment of solid tumors, mobilization of hematopoietic stem cells (HSCs) for autologous transplantations and hematological malignancies.
Further product details are provided in the report……..
C-X-C Chemokine Receptor (CXCR) Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different C-X-C Chemokine Receptor (CXCR) Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
C-X-C Chemokine Receptor (CXCR) Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses C-X-C Chemokine Receptor (CXCR) Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging C-X-C Chemokine Receptor (CXCR) Inhibitors drugs.
C-X-C Chemokine Receptor (CXCR) Inhibitors Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “C-X-C Chemokine Receptor (CXCR) Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in C-X-C Chemokine Receptor (CXCR) Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
C-X-C Chemokine Receptor (CXCR) Inhibitors: Overview
CXCRs (CXC chemokine receptors) are integral membrane proteins that specifically bind and respond to cytokines of the CXC chemokine family. They represent one subfamily of chemokine receptors, a large family of G protein-linked receptors that are known as seven transmembrane (7-TM) proteins, since they span thecell membrane seven times. There are currently seven known CXC chemokine receptors in mammals, named CXCR1 through CXCR7. CXCR1 and CXCR2 are closely related receptors that recognize CXC chemokines that possess an E-L-R amino acid motif immediately adjacent to their CXC motif. CXCR3 is expressed predominantly on T lymphocytes. CXCR4 is the receptor for a chemokine known as CXCL12 (or SDF-1) and, as with CCR5, is utilized by HIV-1 to gain entry into target cells.
The chemokine receptor CXCR5 is selectively expressed on B cells and is involved in lymphocyte homing and the development of normal lymphoid tissue. CXCR6 was formerly called three different names (STRL33, BONZO, and TYMSTR) before being assigned CXCR6 based on its chromosomal location and its similarity to other chemokine receptors in its gene sequence. CXCR7 was originally called RDC-1 (an orphan receptor) but has since been shown to cause chemotaxis in T lymphocytes in response to CXCL12 (the ligand for CXCR4) prompting the renaming of this molecule as CXCR7.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence C-X-C Chemokine Receptor (CXCR) Inhibitors R&D. The therapies under development are focused on novel approaches for C-X-C Chemokine Receptor (CXCR) Inhibitors.
This segment of the C-X-C Chemokine Receptor (CXCR) Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
C-X-C Chemokine Receptor (CXCR) Inhibitors Emerging Drugs
- Motixafortide- BioLineRx
Motixafortide - BL-8040 (formerly known as BKT140 and developed by Biokine Therapeutics Ltd.) is a novel selective inhibitor of the CXCR4 chemokine receptor that is currently being developed for several indications including treatment of solid tumors, mobilization of hematopoietic stem cells (HSCs) for autologous transplantations and hematological malignancies.
- Reparixin - Dompe Farmaceutici
Further product details are provided in the report……..
C-X-C Chemokine Receptor (CXCR) Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different C-X-C Chemokine Receptor (CXCR) Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on C-X-C Chemokine Receptor (CXCR) Inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
C-X-C Chemokine Receptor (CXCR) Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses C-X-C Chemokine Receptor (CXCR) Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging C-X-C Chemokine Receptor (CXCR) Inhibitors drugs.
C-X-C Chemokine Receptor (CXCR) Inhibitors Report Insights
- C-X-C Chemokine Receptor (CXCR) Inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing C-X-C Chemokine Receptor (CXCR) Inhibitors drugs?
- How many C-X-C Chemokine Receptor (CXCR) Inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for C-X-C Chemokine Receptor (CXCR) Inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the C-X-C Chemokine Receptor (CXCR) Inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for C-X-C Chemokine Receptor (CXCR) Inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Dompe Farmaceutici
- BioLineRx
- X4 Pharmaceuticals
- Reparixin
- Motixafortide
- X4P 002
- Mavorixafor
Introduction
Executive Summary
C-X-C Chemokine Receptor (CXCR) Inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
C-X-C Chemokine Receptor (CXCR) Inhibitors - DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
C-X-C Chemokine Receptor (CXCR) Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
C-X-C Chemokine Receptor (CXCR) Inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Motixafortide: BioLineRx
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Reparixin: Dompe Farmaceutici
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Mavorixafor: X4 Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
X4P 002: X4 Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
C-X-C Chemokine Receptor (CXCR) Inhibitors Key Companies
C-X-C Chemokine Receptor (CXCR) Inhibitors Key Products
C-X-C Chemokine Receptor (CXCR) Inhibitors- Unmet Needs
C-X-C Chemokine Receptor (CXCR) Inhibitors- Market Drivers and Barriers
C-X-C Chemokine Receptor (CXCR) Inhibitors- Future Perspectives and Conclusion
C-X-C Chemokine Receptor (CXCR) Inhibitors Analyst Views
C-X-C Chemokine Receptor (CXCR) Inhibitors Key Companies
Appendix
Executive Summary
C-X-C Chemokine Receptor (CXCR) Inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
C-X-C Chemokine Receptor (CXCR) Inhibitors - DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
C-X-C Chemokine Receptor (CXCR) Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
C-X-C Chemokine Receptor (CXCR) Inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Motixafortide: BioLineRx
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Reparixin: Dompe Farmaceutici
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Mavorixafor: X4 Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
X4P 002: X4 Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
C-X-C Chemokine Receptor (CXCR) Inhibitors Key Companies
C-X-C Chemokine Receptor (CXCR) Inhibitors Key Products
C-X-C Chemokine Receptor (CXCR) Inhibitors- Unmet Needs
C-X-C Chemokine Receptor (CXCR) Inhibitors- Market Drivers and Barriers
C-X-C Chemokine Receptor (CXCR) Inhibitors- Future Perspectives and Conclusion
C-X-C Chemokine Receptor (CXCR) Inhibitors Analyst Views
C-X-C Chemokine Receptor (CXCR) Inhibitors Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for C-X-C Chemokine Receptor (CXCR) Inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for C-X-C Chemokine Receptor (CXCR) Inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for C-X-C Chemokine Receptor (CXCR) Inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for C-X-C Chemokine Receptor (CXCR) Inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
